Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Chengkui Zhao"'
Autor:
Zhenyu Wei, Chengkui Zhao, Min Zhang, Jiayu Xu, Nan Xu, Shiwei Wu, Xiaohui Xin, Lei Yu, Weixing Feng
Publikováno v:
BMC Bioinformatics, Vol 25, Iss 1, Pp 1-19 (2024)
Abstract Background CAR-T cell therapy represents a novel approach for the treatment of hematologic malignancies and solid tumors. However, its implementation is accompanied by the emergence of potentially life-threatening adverse events known as cyt
Externí odkaz:
https://doaj.org/article/51af2996258d428f9a698b602b14ca06
Publikováno v:
BMC Bioinformatics, Vol 24, Iss 1, Pp 1-19 (2023)
Abstract Background With the COVID-19 outbreak, an increasing number of individuals are concerned about their health, particularly their immune status. However, as of now, there is no available algorithm that effectively assesses the immune status of
Externí odkaz:
https://doaj.org/article/ea19d8dde15d4b7b987bae2b047c1de5
Autor:
Zhenyu Wei, Jiayu Xu, Chengkui Zhao, Min Zhang, Nan Xu, Liqing Kang, Xiaoyan Lou, Lei Yu, Weixing Feng
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/cd859f76c53d447c8fd135cb8b7ac6da
Autor:
Zhenyu Wei, Jiayu Xu, Chengkui Zhao, Min Zhang, Nan Xu, Liqing Kang, Xiaoyan Lou, Lei Yu, Weixing Feng
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionCAR-T cell therapy is a novel approach in the treatment of hematological tumors. However, it is associated with life-threatening side effects, such as the severe cytokine release syndrome (sCRS). Therefore, predicting the occurrence and d
Externí odkaz:
https://doaj.org/article/a54fee77364448639b4f16981b17bb89
Autor:
Zhenyu Wei, Qi Cheng, Nan Xu, Chengkui Zhao, Jiayu Xu, Liqing Kang, Xiaoyan Lou, Lei Yu, Weixing Feng
Publikováno v:
BMC Bioinformatics, Vol 23, Iss 1, Pp 1-18 (2022)
Abstract Background Chimeric antigen receptor T-cell (CAR-T) therapy is a new and efficient cellular immunotherapy. The therapy shows significant efficacy, but also has serious side effects, collectively known as cytokine release syndrome (CRS). At p
Externí odkaz:
https://doaj.org/article/a805a3c2356346a897e96e33e08e7545
Autor:
Qi Cheng, Bo He, Chengkui Zhao, Hongyuan Bi, Duojiao Chen, Shuangze Han, Haikuan Gao, Weixing Feng
Publikováno v:
BMC Genomics, Vol 22, Iss 1, Pp 1-10 (2021)
Abstract Background Microexons are a particular kind of exon of less than 30 nucleotides in length. More than 60% of annotated human microexons were found to have high levels of sequence conservation, suggesting their potential functions. There is th
Externí odkaz:
https://doaj.org/article/a41ebdf243e64952b53255a68065586c
Autor:
Zhenyu Wei, Jiayu Xu, Chengkui Zhao, Min Zhang, Nan Xu, Liqing Kang, Xiaoyan Lou, Lei Yu, Weixing Feng
Publikováno v:
Frontiers in Immunology; 2024, p1-13, 13p
Autor:
Chengkui Zhao, Nan Xu, Jingwen Tan, Qi Cheng, Weixin Xie, Jiayu Xu, Zhenyu Wei, Jing Ye, Lei Yu, Weixing Feng
Publikováno v:
Briefings in Bioinformatics. 23
Short hairpin RNA (shRNA)-mediated gene silencing is an important technology to achieve RNA interference, in which the design of potent and reliable shRNA molecules plays a crucial role. However, efficient shRNA target selection through biological te
Autor:
Hongyuan Bi, Qi Cheng, Chen Duojiao, Shuangze Han, Chengkui Zhao, Weixing Feng, Bo He, Haikuan Gao
Publikováno v:
BMC Genomics
BMC Genomics, Vol 22, Iss 1, Pp 1-10 (2021)
BMC Genomics, Vol 22, Iss 1, Pp 1-10 (2021)
Background Microexons are a particular kind of exon of less than 30 nucleotides in length. More than 60% of annotated human microexons were found to have high levels of sequence conservation, suggesting their potential functions. There is thus a need
Autor:
Zhenyu Wei, Qi Cheng, Nan Xu, Chengkui Zhao, Jiayu Xu, Liqing Kang, Xiaoyan Lou, Lei Yu, Weixing Feng
Publikováno v:
BMC bioinformatics. 23(1)
Background Chimeric antigen receptor T-cell (CAR-T) therapy is a new and efficient cellular immunotherapy. The therapy shows significant efficacy, but also has serious side effects, collectively known as cytokine release syndrome (CRS). At present, s